Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
Results of a randomised trial from Uganda in this week’s issue of THE LANCET suggest that the drug combination of amodiaquine and sulfadoxinepyrimethamine might offer the optimal treatment for malaria in terms of efficacy and cost-effectiveness in this region.
Sharply increased demand for artemether-lumefantrine, an artemisinin-based combination therapy (ACT) used to treat malaria, is likely to result in a shortage from now until at least March 2005. ACTs are currently the most effective medicines available to treat falciparum malaria -- the deadliest form of the disease.
The University of California, Berkeley, has signed an agreement with the Samoan government to isolate from an indigenous tree the gene for a promising anti-AIDS drug and to share any royalties from sale of a gene-derived drug with the people of Samoa.
Malaria research scientists from around the globe have published new insights into the international burden of malaria and what can be done about it.
Imported resistance has rendered ineffective the two affordable malaria drugs which have been the mainstay of malaria treatment in Africa for forty years, according to experts writing today in the journal Science.
Within the next five years, international organizations and world leaders should begin collectively to contribute $300 million to $500 million annually to create a global subsidy that would make new combination malaria treatments available to the world's poor for as little as 10 cents per treatment course
GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a collaborative agreement, to develop a new-fixed dose artemisinin combination therapy drug (ACT), combining chlorproguanil, dapsone and artesunate (CDA) for the treatment of malaria.
Widespread use of a new fast-acting and potent treatment for malaria is finally on the horizon in Africa, where malaria is the number one killer of children.
More than 600 million people, most of them children living in sub-Saharan Africa, face the daily threat of death from malaria because new, effective treatments are not available where they live. Existing, cheaper medicines, which have been used for many years, are no longer effective in most places because the malaria parasite has developed resistance to them.